Kezar Life Sciences

Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced a strategic collaboration and license agreement with US firm Kezar Life Sciences Inc. (NASDAQ: KZR) to develop and commercialize zetomipzomib, Kezar’s novel first-in-class selective immunoproteasome inhibitor, in Greater China, South Korea, and Southeast Asia. This partnership aims to leverage the…